India has clamped down on the country's burgeoning market for irrational fixed-dose combinations (FDCs), weeding out more than 300 such products – a move that is seen as denting the industry sharply but being welcomed by physicians given the lack of therapeutic rationale for most of these medicines and the growing challenge of drug resistance in the case of anti-infectives.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?